Proliferating cell nuclear antigen (PCNA), p53 and MDM2 expression in Hodgkin’s disease

CONTEXT AND OBJECTIVE: Tumor cells in Hodgkin’s disease (HD) express cell proliferation markers that are evaluated according to the oncogenes involved or the expression of their proteins. Correlations between the protein expression grade and clinical data are now important for disease prognosis. DES...

ver descrição completa

Detalhes bibliográficos
Autores: Pinheiro, Gevina Silva, Silva, Maria Regina Régis, Rodrigues, Celso Arrais, Kerbauy, José, Oliveira, José Salvador Rodrigues de
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2007
País:Brasil
Recursos:Associação Paulista de Medicina
Repositorio:São Paulo medical journal (Online)
Idioma:inglés
OAI Identifier:oai:ojs.diagnosticoetratamento.emnuvens.com.br:article/2073
Acesso em linha:https://periodicosapm.emnuvens.com.br/spmj/article/view/2073
Access Level:acceso abierto
Palavra-chave:Antígeno nuclear de célula em proliferação
Genes p53
Proteínas proto-oncogênicas c-mdm2
Doença de Hodgkin
Imunohistoquímica
Proliferating cell nuclear antigen
P53 genes
Proto-oncogene proteins c-mdm2
Hodgkin disease
Immunohistochemistry
Descrição
Resumo:CONTEXT AND OBJECTIVE: Tumor cells in Hodgkin’s disease (HD) express cell proliferation markers that are evaluated according to the oncogenes involved or the expression of their proteins. Correlations between the protein expression grade and clinical data are now important for disease prognosis. DESIGN AND SETTING: This was a retrospective analysis on proliferating cell nuclear antigen (PCNA), p53 and MDM2 (murine double minute-2) expression using immunohistochemistry, on formalinfi xed, paraffi n-embedded tissues from diagnostic biopsies on 51 patients with HD. The study was conducted at the Division of Hematology and Transfusion Medicine, Hospital São Paulo, Universidade Federal de São Paulo. METHODS: Antigen expression was evaluated as the proportions of positive Hodgkin and ReedSternberg (HRS) cells and reactive lymphocytes (L), which were compared using Spearman correlation coeffi cients. The Friedman test was used for comparisons between the markers. The Pearson test was used to investigate associations between marker expression and clinical and laboratory parameters, marrow involvement, complete remission (CR) and overall survival (OS) rates. RESULTS: There was overexpression of antigen proteins in HRS, in relation to L (p < 0.001). In HRS, MDM2 was higher than p53 and PCNA (p < 0.003), while the latter two were equivalent. In L, p53 was lower than MDM2 and PCNA (p < 0.001), while the latter two were equivalent. There was no relationship between protein expression and clinical and laboratory variables or outcome. CONCLUSIONS: PCNA, p53 and MDM2 are tumor markers for HD, but showed no clinical or prognostic signifi cance in our analysis.